Weight-Loss Drugs Are Changing. Here’s What to Know – Bloomberg.com
Weight-Loss Drugs Are Changing. Here’s What to Know Bloomberg.com Weight-loss pill approval set to accelerate food industry product overhauls Reuters U.S. regulators approve Wegovy pill for weight loss NPR FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss The American Journal of Managed Care® (AJMC®) The FDA just approved the first GLP-1 weight-loss pill. Here’s what to […]
Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China
Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes of patients with T2D and CKD in China who initiated sodium-glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RA). Design Retrospective cohort study. Setting […]
Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinsons disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
Introduction Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson’s disease (PD); however, clinical evidence has not yet been established and remains controversial. This clinical study aims to assess the efficacy, disease-modifying effects, safety and optimal dose of oral semaglutide tablets, a GLP-1 receptor agonist, in idiopathic patients with […]
FDA Approves Novo Nordisk’s Wegovy Pill, the First and Only Oral GLP-1 for Weight Loss in Adults
PLAINSBORO, N.J., Dec. 22, 2025 /PRNewswire/ — Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US.3 Wegovy pill is used with a reduced…
Weight-loss pill approval spurs food industry overhaul | REUTERS
Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say. #News #USA #WeightLoss #GLP #Reuters #Newsfeed Read the story here: https://reut.rs/4atbzuB 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: https://www.reuters.com/ Follow […]
SPOTTED: Oikos Fusion Cultured Dairy Drinks
These are specifically made for users of Ozempic and other GLP-1 drugs to help them build and maintain muscle mass. Cool. But I like to think of these as a mashup of Oikos and Activia yogurts. (Spotted by Robbie at Walmart.) If you’re out shopping and see new products, snap a picture of them, and […]
CMS to cross threshold of obesity drug coverage
In a threshold event in the U.S., Medicare is planning to break through its obesity coverage barrier with a voluntary test of a model designed to enable Medicare Part D plans and state Medicaid programs to cover GLP-1 drugs prescribed for weight management.
Natural Ozempic? 6 GLP-1 Foods That Work Just Like the Shot
US Health Agency Unveils Weight-loss Drug Coverage Model
The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare… Reuters Health Information
Healthcare, Vol. 14, Pages 51: Translational Lifestyle Medicine Approaches to Cardiovascular–Kidney–Metabolic Syndrome
Healthcare, Vol. 14, Pages 51: Translational Lifestyle Medicine Approaches to Cardiovascular–Kidney–Metabolic Syndrome Healthcare doi: 10.3390/healthcare14010051 Authors: Zacharias Papadakis Cardiovascular–Kidney–Metabolic (CKM) syndrome arises from interrelated cardiovascular, renal, and metabolic pathways that require coordinated therapeutic strategies. This narrative review synthesizes recent systematic reviews, meta-analyses, and original studies to evaluate the translational application of lifestyle medicine (LM) for […]